Who Qualifies for GLP-1? The Official 2026 Breakdown

Last reviewed: June 12, 2026

Last updated: June 12, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 qualification has expanded dramatically since 2023, moving beyond diabetes management into precision weight loss medicine. The American Medical Association and endocrinology societies now recognize GLP-1 therapy as appropriate for adults with BMI ≥27 and weight-related comorbidities, or BMI ≥30 regardless of other conditions. PlexusDx evaluates each patient individually to determine the right medication and protocol.

Standard BMI and Weight Criteria for GLP-1 Eligibility

Body Mass Index remains a starting point for GLP-1 qualification, though it is no longer the only factor. Adults with a BMI of 30 or higher generally qualify for GLP-1 therapy. Those with a BMI between 27 and 29.9 who have at least one weight-related health condition—such as high blood pressure, type 2 diabetes, heart disease, or sleep apnea—also meet eligibility standards. PlexusDx reviews your complete health profile to confirm qualification before beginning treatment.

Weight loss potential with GLP-1 therapy averages 15-22% of body weight over 68 weeks according to major clinical trials. This outcome has made GLP-1 medications appropriate for a broader population than previously thought. Your specific response may vary based on genetics, lifestyle, and medication type. PlexusDx uses evidence-based assessment to match you with the most suitable option.

Weight-Related Health Conditions That Qualify You

Chronic diseases linked to excess weight make individuals eligible for GLP-1 therapy even at lower BMI levels. Hypertension, type 2 diabetes, coronary artery disease, heart failure, stroke history, and obstructive sleep apnea all count toward qualification. Additionally, metabolic syndrome, non-alcoholic fatty liver disease, and osteoarthritis are recognized comorbidities that expand eligibility. PlexusDx clinicians review your medical history to identify whether you meet criteria through documented conditions.

The presence of even one significant weight-related condition at BMI 27-29.9 opens access to GLP-1 therapy. This shift reflects growing clinical evidence that weight loss reduces complications and improves survival in people with these diseases. Your primary care provider's records and recent lab work help PlexusDx confirm eligibility quickly. Starting therapy early can prevent disease progression and reduce medication burden over time.

Age, Pregnancy, and Special Population Requirements

GLP-1 therapy is approved for adults aged 18 and older in the United States. Adolescents aged 12-17 may qualify for specific GLP-1 medications under pediatric indications, though PlexusDx primarily serves adult patients. Pregnant women and those planning pregnancy should not use GLP-1 medications due to limited safety data; discontinuation is recommended three months before attempting conception. Lactating women should discuss GLP-1 use with their healthcare provider, as limited information exists about excretion into breast milk.

Patients with a personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) cannot use GLP-1 therapy due to animal study findings showing thyroid C-cell tumors. This is a firm contraindication listed in all GLP-1 prescribing information. Kidney or liver disease may require dose adjustments or closer monitoring. PlexusDx performs a comprehensive medical screening to identify any contraindications before enrollment.

How PlexusDx Determines Your Personalized GLP-1 Qualification

PlexusDx uses a multi-step qualification process that goes beyond BMI and basic criteria. Your initial consultation includes a detailed health questionnaire, review of current medications, and assessment of weight-related symptoms. Blood pressure, fasting glucose, and liver function may be requested to ensure safety. PlexusDx clinicians then match you with semaglutide injection, oral semaglutide, tirzepatide, or a dual-compound protocol based on your unique profile.

The Precision Peptide Genetic Test offered by PlexusDx adds another layer of personalization after your first month of treatment. This peptide-pathway genetic analysis examines 14 metabolic pathways and 150+ genetic insights, including variants in GLP1R, GIPR, FTO, and MC4R genes. Understanding your genetic predispositions helps optimize medication selection and dosing strategy. Semaglutide Injection starts at $149 per month, with the genetic test available as a $99 add-on to refine your long-term plan.

Accessing GLP-1 Therapy Without Insurance Requirements

One major advantage of PlexusDx is that insurance is never required. Patients pay flat monthly rates regardless of the dose level your provider prescribes—your dose may need to go up, but your price won't. This pricing structure removes barriers that have historically prevented qualified individuals from accessing GLP-1 therapy. Compounded semaglutide injection, manufactured by licensed 503A compounding pharmacies, costs from $149 per month across all commitment tiers.

Payments are HSA and FSA eligible, allowing you to use tax-advantaged health savings accounts. PlexusDx serves all 50 states with no membership fees or hidden charges. The combination of straightforward pricing, genetic personalization, and access across the country makes it feasible for more qualified patients to begin GLP-1 therapy. Your eligibility decision can be made and confirmed within days of your initial assessment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I qualify for GLP-1 if my BMI is between 27 and 29?

Yes, you may qualify if you have at least one weight-related health condition such as high blood pressure, type 2 diabetes, heart disease, or sleep apnea. PlexusDx reviews your complete medical history to confirm eligibility. If you meet criteria, semaglutide injection is available starting at $149 per month.

What percentage of weight can I expect to lose with GLP-1 therapy?

Clinical trials show average weight loss of 15-22% of body weight over 68 weeks with GLP-1 medications. Individual results vary based on genetics, adherence, diet, and exercise. PlexusDx's Precision Peptide Genetic Test helps predict your likely response by analyzing genes affecting appetite control and metabolic rate.

Does PlexusDx require insurance or a membership fee?

No. PlexusDx serves all 50 states without insurance requirements or membership costs. Your dose may increase, but your monthly price won't—semaglutide injection starts at $149 per month flat. Payments are HSA and FSA eligible for added savings.

Are there any medical conditions that make me ineligible for GLP-1?

Yes. A personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) are firm contraindications. Severe kidney or liver disease may also require alternative approaches. Pregnancy and lactation are not appropriate times to start GLP-1 therapy. PlexusDx screening identifies any contraindications before enrollment.

How does the PlexusDx Precision Peptide Genetic Test help with my eligibility?

The genetic test ($99 add-on after month one) analyzes 14 metabolic pathways and examines variants in GLP1R, GIPR, FTO, and MC4R genes. This helps PlexusDx predict whether you'll respond best to semaglutide, tirzepatide, or a dual-compound approach, refining your personalized qualification and treatment plan.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.